Due to the current situation related to the coronavirus (COVID-19), study teams may experience delays in responding to signups and scheduling patients on StudyPages.A study team member will respond to you as soon as possible.

UC Davis Health Clinical Studies

A Study of Experimental Stem Cell Injection for Central Retinal Vein Occlusion (vision loss due to decreased blood supply in eye)

Volunteer for research at UC Davis Eye Center

Central retinal vein occlusion (CRVO) is an eye condition often associated with permanent loss of vision. CRVO blocks the blood supply to the retina. The retina is the part of the eye that captures the images that the eye sees and transmits the information to the brain. This blockage can damage your retina causing vision loss. In this study, we aim to learn more about a new procedure that involves injecting your own (autologous) stem cells into the eye. This approach is investigational and we do not have a lot of information about it. However, this stem cell procedure was used in a smaller study of 9 patients with different eye diseases including 1 patient with CRVO. The study was conducted by the same team led by Dr. Susanna Park at UC Davis. The aim of the current larger study is to get more information about this new procedure for patients with vision loss from CRVO. All participants will be randomly assigned to 1 of 2 groups. Both groups will receive one stem cell injection in the study eye. You will not be told which group you are in until the end of the study. Group 1 will have a bone marrow aspiration and stem cell injection during Study Period 1 or at the beginning of the study. During Study Period 2 or around 6 months into the study, Group 1 will have a sham or fake aspiration and a sham or fake injection. Group 2 will have a sham or fake aspiration and a sham or fake injection during Study Period 1 or at the beginning of the study. During Study Period 2 or around 6 months into the study, Group 2 will have bone marrow aspiration and stem cell injection.

Biological study, Phase [1, 2]
Any, age 18 years or older

A Comparison Study of the Experimental Human Acellular Vessel For Dialysis in End-Stage Renal Disease

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

This research study is for patients with kidney failure, undergoing hemodialysis with a dialysis catheter. For long term hemodialysis, it's best to create a more permanent and safe route to connect your blood stream to the dialysis machine. There are many ways to do this including surgically implanting a graft (a short piece of tubing). Another option is to surgically connect your artery and vein. This connection is called an autologous arteriovenous fistula or AVF. This study will compare a new investigational graft developed by Humacyte (the Human Acellular Vessel or HAV) with an AVF. This study will compare the ability of the HAV to function as an alternative to AVF for vascular access during hemodialysis.

Biological study, Phase 3
Any, age 18 years or older

A Study of Experimental Cellular Immunotherapy For Living Donor Kidney Transplants

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

The main goal of this research is to determine if the experimental medicine MDR 101 can help kidney transplant patients. The study team will test if a single infusion of MDR 101 will create a state of “tolerance” in the kidney recipient. The study team wants to learn if this treatment will allow patients to minimize anti-rejection medications. They hope patients can stay off these medications for at least 2 years or longer. MDR 101 is processed from blood stem cells from the same person that is the kidney donor. This study will help better understand the effects of this stem cell therapy on kidney transplantation and life after transplant.

Drug study, Phase 3
Any, age 18 to 65 years old

Multicentre, Randomized, Open-Label, Phase III Clinical Trial for Advanced Nasopharyngeal Carcinoma Patients

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

This study is a multi-center, randomized, open label, Phase III clinical trial. Drugs used in chemotherapy, such as gemcitabine and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving an infusion of a person's cytotoxic T lymphocytes (CTL) that have been treated in the laboratory may help the body build an effective immune response to kill tumor cells. Giving combination chemotherapy together with laboratory-treated T lymphocytes may kill more tumor cells. This Phase III trial is to assess if combined gemcitabine-carboplatin (GC) followed by adoptive T-cell therapy would improve clinical outcome for patients with advanced nasopharyngeal carcinoma (NPC). It is also the world's first, and largest, Phase 3 T-cell therapy cancer trial ever conducted, and enrollment is ongoing for 330 patients from 29 hospital centers across Asia and the United States. This clinical trial is conducted on the back of a successful Phase 2 NPC trial involving 38 patients at the National Cancer Centre, Singapore. This trial produced the best published 2-year (62.9%), and median overall survival (OS) data (29.9 months) in 35 patients with advanced NPC who received autologous EBV-specific CTL. Kindly see https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978790/ for the Phase 2 publication titled "Adoptive T-cell Transfer and Chemotherapy in the First line treatment of Metastatic and/or Locally Recurrent Nasopharyngeal Carcinoma".

Biological study, Phase 3
Any, age 21 years or older

Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant

Study looking at stem cell gene therapy to treat patients with HIV and lymphoma

This study is to test the safety of combining stem cell therapy with gene therapy to treat lymphoma. For gene therapy, researchers in a laboratory will add small stretches of DNA called “anti-HIV genes” into your stem cells to make the gene therapy product used in this study. The type of anti-HIV genes and therapy in this study might make your immune cells more resistant to HIV. The goal of the study is to develop an immune system that can actively prevent new immune cells from getting infected with HIV, while the older cells die due to HIV. This new immune system might be able to fight the spread of HIV even without HIV medications. The gene therapy product in combination with your clinically indicated stem cell transplant in this study is considered experimental because it has not been used in human clinical trials and has not been approved by the Food and Drug Administration (FDA) for treatment of HIV. A similar gene therapy product has been used in other human clinical trials with stem cell therapy.

Procedure study, Phase I/II
Any, age 19 to 100 years old